Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances
- 11 August 2012
- journal article
- review article
- Published by Springer Science and Business Media LLC in The Esophagus
- Vol. 47 (9), 941-960
- https://doi.org/10.1007/s00535-012-0642-8
Abstract
Neuroendocrine tumors (NETs) [carcinoids, pancreatic neuroendocrine tumors (pNETs)] are becoming an increasing clinical problem because not only are they increasing in frequency, but they can frequently present with advanced disease that requires diagnostic and treatment approaches different from those used in the neoplasms that most physicians are used to seeing and treating. In the past few years there have been numerous advances in all aspects of NETs including: an understanding of their unique pathogenesis; specific classification systems developed which have prognostic value; novel methods of tumor localization developed; and novel treatment approaches described. In patients with advanced metastatic disease these include the use of newer chemotherapeutic approaches, an increased understanding of the role of surgery and cytoreductive methods, the development of methods for targeted delivery of cytotoxic agents, and the development of targeted medical therapies (everolimus, sunitinib) based on an increased understanding of the disease biology. Although pNETs and gastrointestinal NETs share many features, recent studies show they differ in pathogenesis and in many aspects of diagnosis and treatment, including their responsiveness to different therapies. Because of limited space, this review will be limited to the advances made in the management and treatment of patients with advanced metastatic pNETs over the past 5 years.Keywords
This publication has 208 references indexed in Scilit:
- Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapyNature Reviews Gastroenterology & Hepatology, 2012
- Pancreatic Endocrine Tumors With Major Vascular Abutment, Involvement, or Encasement and Indication for ResectionArchives of Surgery, 2011
- Implications of Incidentally Discovered, Nonfunctioning Pancreatic Endocrine TumorsArchives of Surgery, 2011
- Somatostatin Receptor-Targeted Radionuclide Therapy in Patients with Gastroenteropancreatic Neuroendocrine TumorsEndocrinology and Metabolism Clinics of North America, 2011
- Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomasCancer Treatment Reviews, 2010
- Regulatory Peptides from Chromogranin A and Secretogranin IICellular and Molecular Neurobiology, 2010
- Molecular targeted therapies in the treatment of gastroenteropancreatic neuroendocrine tumorsTargeted Oncology, 2009
- Combined liver surgery and RFA for patients with gastroenteropancreatic endocrine tumors presenting with more than 15 metastases to the liverEuropean Journal of Surgical Oncology, 2009
- Gastroenteropancreatic neuroendocrine tumoursThe Lancet Oncology, 2008
- TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading systemVirchows Archiv, 2006